You are here: Industry Insights > Mavenclad

News List

Multiple sclerosis trial focusing on people who can’t walk begins recruitment pharmatimes
November 20, 2020
A new trial focusing solely on multiple sclerosis patients who can’t walk is set to begin recruiting participants.
FDA green light for Merck's Mavenclad pharmatimes
April 02, 2019
German pharmaceutical giant Merck has announced the US Food and Drug Administration (FDA) approval of its Mavenclad (cladribine) tablets in various forms of multiple sclerosis (MS).
Up to 10-years of follow-up data reaffirm safety profile of Mavenclad (cladribine tablets) worldpharmanews
October 12, 2018
Merck, the vibrant science and technology company, today announced the presentation of new data for MAVENCLAD® (cladribine tablets) at the 34th Congress of the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS) in Berlin, German
Merck’s MS pill Mavenclad launched in the UK and Ireland pharmatimes
September 22, 2017
Merck’s Mavenclad is now available in the UK and Ireland to treat highly active relapsing multiple sclerosis in adults.
European Commission Grants Approval for Mavenclad americanpharmaceuticalreview
August 28, 2017
Merck announced the European Commission (EC) has granted marketing authorization for MAVENCLAD 10mg (Cladribine Tablets) for the treatment of highly active relapsing multiple sclerosis (RMS) in the 28 countries of the European Union (EU) in addition to No